<DOC>
	<DOCNO>NCT00332137</DOCNO>
	<brief_summary>The muscarinic antagonist tolterodine widely use treat urinary urge incontinence . Though acteylcholine primary excitatory neurotransmitter gastrointestinal tract , phase III trial suggest tolterodine infrequently cause constipation . Therefore , objective study assess tolterodine affect speed food travel stomach , intestine colon ( i.e. , gastrointestinal colonic transit ) healthy subject .</brief_summary>
	<brief_title>Effects Tolterodine , Non-Specific Muscarinic Antagonist , Gastrointestinal Transit Healthy Subjects</brief_title>
	<detailed_description>The specific aim study test hypotheses non-specific muscarinic antagonist tolterodine : - ) delay colonic transit proximal colonic empty rate ; ii ) delay gastric emptying ; iii ) delay small intestinal transit compare placebo healthy subject .</detailed_description>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Muscarinic Antagonists</mesh_term>
	<criteria>Age 1870 year old . Absence gastrointestinal symptom characterize bowel symptom questionnaire absence significant anxiety depression characterize hospital anxiety depression questionnaire . Able understand willing sign inform consent . Females nonpregnant , nonlactating , willing use clinically approve method contraception two week prior Day 0 1 week last dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>